A subgroup analysis of the CATNON trial with 154 IDHwt astrocytoma with molecular features of glioblastoma showed that MGMT promotor methylation was prognostic for overall survival but not predictive for temozolomide chemotherapy in this cohort [7]. The gene discussed is MGMT; the disease is glioblastoma.